Women with early menopause and surgical menopause should be closely monitored for CHD.

Age at menopause has an inverse dose-response relationship with coronary heart disease risk.

Clinically significant benefit on perceived effect and frequency of symptoms and sleep quality.

Night work has been associated with changes in ovulation and preterm labor.

Long-term study in postmenopausal women with osteoporosis sees few cases.

Early menopause affects approximately 5% of women and is associated with increased risk of non-fatal and fatal CVD and mortality.

No associations with cancer seen, however.

Increased VTE risk observed with oral, but not transdermal, formulations.

No significant increased risk of venous thromboembolism was seen with transdermal products.

Risk increased by 13% relative to women never experiencing vasomotor symptoms.

Results from secondary analysis of 2 randomised trials.

Correct diagnosis has implications for treatment and prognosis.

Less than 2% of women adhere to 3 critical components for risk reduction.

Women with PCOS may benefit from increased cancer surveillance.